15.56
전일 마감가:
$15.14
열려 있는:
$15.01
하루 거래량:
833.20K
Relative Volume:
2.07
시가총액:
$485.95M
수익:
$322.67M
순이익/손실:
$-61.63M
주가수익비율:
-7.917
EPS:
-1.9654
순현금흐름:
$-124.21M
1주 성능:
+5.99%
1개월 성능:
-33.13%
6개월 성능:
-30.29%
1년 성능:
-7.77%
Fulgent Genetics Inc Stock (FLGT) Company Profile
명칭
Fulgent Genetics Inc
전화
626-350-0537
주소
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
FLGT
Fulgent Genetics Inc
|
15.56 | 472.83M | 322.67M | -61.63M | -124.21M | -1.9654 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 업그레이드 | UBS | Neutral → Buy |
| 2023-12-07 | 개시 | UBS | Neutral |
| 2022-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-11-18 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-02-04 | 재개 | Piper Sandler | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Underperform |
| 2021-01-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-11-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-08-20 | 개시 | Oppenheimer | Outperform |
| 2020-05-29 | 개시 | BTIG Research | Buy |
| 2019-11-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-03-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Fulgent Genetics Inc 주식(FLGT)의 최신 뉴스
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (FLGT) Edition - Stock Traders Daily
Published on: 2026-03-19 03:58:12 - baoquankhu1.vn
Fulgent Genetics Completes $56.9M Acquisition of Bako Diagnostics and StrataDx to Expand Precision Medicine Services - Minichart
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx - BioSpace
Fulgent Genetics completes $56.9M pathology lab acquisitions By Investing.com - Investing.com India
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Fulgent Genetics Acquires Bako Diagnostics Assets, StrataDx for $56.9 Million - marketscreener.com
Fulgent Genetics completes $56.9M pathology lab acquisitions - Investing.com
Fulgent Genetics Expands Dermatology Footprint With Key Acquisitions - TipRanks
Fulgent Genetics (NASDAQ: FLGT) buys Bako Diagnostics and StrataDx - Stock Titan
Fulgent Genetics (NASDAQ:FLGT) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Fulgent Genetics (FLGT) Stock Analysis Report | Financials & Insights - Benzinga España
Fulgent Genetics seeks new collaborations at Copenhagen ADPD2026 event - Traders Union
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics: A Major Market Misconception (NASDAQ:FLGT) - Seeking Alpha
Fulgent Genetics (NASDAQ: FLGT) CEO pays $10.7M to cancel share forward - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - FinancialContent
Fulgent Genetics (FLGT) Earnings Transcript - AOL.com
Aug Sectors: Should I hold or sell Fulgent Genetics Inc now2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
Fulgent Genetics Hits New 52-Week Low at $14.01 Amid Declining Performance - Markets Mojo
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Technical Analysis: Is Fulgent Genetics Inc a top pick in the sectorQuarterly Earnings Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Fulgent Genetics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:FLGT) 2026-03-05 - Seeking Alpha
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - FinancialContent
FLGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulgent Genetics (FLGT) CSO has shares withheld to cover RSU taxes - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CEO has shares withheld for taxes - Stock Titan
Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused ExpansionWhat's Changed - Yahoo Finance
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating - marketscreener.com
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results - marketscreener.com
Assessing Fulgent Genetics (FLGT) Valuation After Earnings Outperformance And AI Oncology Pipeline Progress - simplywall.st
A Look At Fulgent Genetics (FLGT) Valuation After 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Fulgent Genetics (NASDAQ:FLGT) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Fulgent Q4 2025 slides: EPS beats, but customer loss drives stock plunge - Investing.com Australia
Fulgent Genetics (FLGT) Loss Widening In Q4 2025 Tests Bullish Growth Narratives - simplywall.st
Fulgent Genetics (FLGT) Reports Strong Q4 Revenue Growth - GuruFocus
Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance - MarketBeat
Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Highlights: Na - GuruFocus
Fulgent Genetics Q4 Earnings Call Highlights - MarketBeat
Fulgent Genetics (FLGT) Reports Strong Q4 Earnings Despite Reven - GuruFocus
Earnings call transcript: Fulgent Genetics Q4 2025 beats EPS estimates, stock tumbles - Investing.com
Fulgent Genetics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fulgent Genetics earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada
Fulgent Genetics, Inc. (FLGT) Q4 Earnings Top Estimates - Yahoo Finance
Fulgent Genetics Posts 2025 Results and 2026 Outlook - TipRanks
Fulgent Genetics (FLGT) Reports Q4 Revenue Below Expectations - GuruFocus
Fulgent Genetics Inc (FLGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):